SEBI Reg. Investment Advisor

Download App
Help Center Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Neuland Laboratories Ltd (NEULANDLAB)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524558 NSE: NEULANDLAB Pharmaceuticals & Drugs | Small Cap | Neuland Laboratories Share Price

₹18,942.05 519.25 (2.82%)

As on 20-Jul'26 16:59

Neuland Laboratories Ltd (NEULANDLAB)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524558 NSE: NEULANDLAB Pharmaceuticals & Drugs | Small Cap | Neuland Laboratories Share Price

₹18,942.05 519.25 (2.82%)

As on 20-Jul'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹23,636 Cr.
Current Price
₹18,942.1
52-Week Low / High
₹11,500 / 20,072
TTM EPS
₹283
TTM Sales
₹2,023 Cr.
Book Value per Share
₹1,453.6
P/E Ratio
65.09
Higher than its 5-year historical median
Industry PE
50
Price to Book (P/B)
12.67
Higher than its 5-year historical median
Price to Sales (P/S)
11.68
Higher than its 5-year historical median
EV/EBITDA
38.91
Higher than its 5-year historical median
Dividend Yield
0.18%
Profitability Efficiency
Return on Equity (ROE)
21.47%
Outperforms industry median
Return on Capital Employed (ROCE)
27.55%
Outperforms industry median
Return on Assets (ROA)
14.22%
Operating Profit Margin
28.6%
Net Profit Margin
17.95%
Gross Profit Margin
28.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
36.98%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
77.86%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
39.96%
Asset Quality
Promoter Holding
32.63%
Pledged shares (%) of Promoter's holding (%)
2.29%
Reserves
₹1,852 Cr.
Equity
₹12.8 Cr.
Face Value
₹10
All Time Low / High
₹14.26 / 20072.00

Neuland Laboratories stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Somewhat Good
Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong
Check Price chart
Q.1 Is Neuland Laboratories Ltd a good quality company?
Neuland Laboratories Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Neuland Laboratories Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Neuland Laboratories Ltd vs industry peers?
Neuland Laboratories Ltd revenue CAGR is 14.13%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Neuland Laboratories Ltd?
Promoters hold 32.63% of the Neuland Laboratories Ltd, with 2.29% of their stake pledged, indicating low pledge risk.
Q.1 Stock return of Neuland Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 35.2% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Neuland Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ15.9%4%4%7.8%12.8%9.4%21%33.6%23.5%27.6%-
Value Creation
Index ⓘ		0.1-0.7-0.7-0.4-0.1-0.30.51.50.71.0-

Growth Parameters ⓘ
Sales ⓘ5795276677639379511,1911,5591,4772,0232,023
Sales YoY Gr.--8.9%26.4%14.4%22.8%1.5%25.3%30.8%-5.2%37%-
Adj EPS ⓘ53.113.815.513.156.850.6131.3233.6164.1280.1283
YoY Gr.--73.9%11.9%-15.5%334%-10.9%159.7%77.9%-29.7%70.7%-
BVPS (₹) ⓘ260273.5541.5549.2608.7650.6769.7994.31,182.31,453.61,453.6
Adj Net
Profit ⓘ		47.212.319.916.872.864.9168300211359363
Cash Flow from Ops. ⓘ38.911.569.656.618960.4239260318348-
Debt/CF from Ops. ⓘ4.927.73.34.60.93.80.50.30.40.6-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ14.9%16.6%19.3%37%
Adj EPS ⓘ20.3%37.6%28.7%70.7%
BVPSⓘ21.1%19%23.6%23%
Share Price 34.6% 55% 80.5% 33%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		132.23.22.49.8818.526.515.121.219.5
Op. Profit
Mgn % ⓘ		18.59.69.513.515.915.223.729.722.328.628.3
Net Profit
Mgn % ⓘ		8.22.332.27.86.814.119.214.317.818
Debt to
Equity ⓘ		0.81.30.30.40.20.30.10.10.10.10.1
Working Cap
Days ⓘ		22028424222520721819818320418098
Cash Conv.
Cycle ⓘ		106152121116106123115981008849

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales5795276677639379511,1911,5591,4772,023
Operating Expenses ⓘ + 4734776096617908099201,0971,1551,450
Manufacturing Costs71817798116131136157163192
Material Costs263238366380438422478577588756
Employee Cost 8596104118144176195249261329
Other Costs ⓘ 556261659280111114143174
Operating Profit ⓘ 1065058101146142271462322573
Operating Profit Margin (%) 18.3%9.5%8.7%13.3%15.6%15.0%22.8%29.6%21.8%28.3%
Other Income ⓘ + 153416210132130
Exceptional Items ⓘ 00000000760
Interest ⓘ 2119162218131314824
Depreciation ⓘ 19222631404953606692
Profit Before Tax ⓘ 6714205210582215401345488
Tax ⓘ 20243725185210186125
Profit After Tax 461216168064163300259363
PAT Margin (%) 8.0%2.2%2.4%2.1%8.6%6.7%13.7%19.2%17.6%18.0%
Adjusted EPS (₹)52.213.312.612.462.649.5127.1233.5202.2283.0
Dividend Payout Ratio (%)0%0%9.50%16.20%8%10.10%7.90%6%5.90%12%

Valuation of Neuland Laboratories - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 2322446967067828369881,2771,5181,866
Share Capital ⓘ 991313131313131313
Reserves ⓘ 2232356836937698239751,2641,5051,853
Debt +181303210246145196854591161
Long Term Debt30103617788104744591161
Short Term Debt151199149168579211000
Minority Interest0000000000
Trade Payables89129124120157123178199261279
Others Liabilities ⓘ 383395101159240227328311309623
Total Liabilities ⓘ 8851,0711,1301,2301,3241,3821,5791,8312,1782,928

Fixed Assets

Net Fixed Assets ⓘ +4364455126236977487388059551,177
Gross Block4554835757148269139531,0701,2381,531
Accumulated Depreciation19386492130166215265283355
CWIP ⓘ 20126104241720414648211
Investments ⓘ 888874111092
Inventories135175193220248265279350386510
Trade Receivables181194164190218234362374316541
Cash Equivalents 12173746181959115257354
Others Assets ⓘ 9310611212011991100140108133
Total Assets ⓘ 8851,0711,1301,2301,3241,3821,5791,8312,1782,928

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 3912705718960239260318348
PBT ⓘ 6714205210582215401345488
Adjustment ⓘ 4440395840667862-12103
Changes in Working Capital ⓘ -55-3916-4949-67-11-9159-139
Tax Paid ⓘ -16-3-5-5-5-21-44-112-75-103
Cash Flow From Investing Activity ⓘ + -42-116-77-49-84-96-61-150-298-424
Capex -41-133-63-48-105-98-65-144-110-396
Net Investments -115-16-619222-100115
Others ⓘ 0115212-8-88-143
Cash Flow From Financing Activity ⓘ + -010512-5-11438-136-692521
Net Proceeds from Shares ⓘ 001250000000
Net Proceeds from Borrowing ⓘ -579-3992223-33-285561
Interest Paid ⓘ -21-22-25-24-18-14-13-14-8-24
Dividend Paid ⓘ -100-5-3-4-6-13-18-15
Others ⓘ 2748-4914-11532-84-14-4-1
Net Cash Flow ⓘ -3042-93414144-55

Financial Ratio

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)22.394.983.442.2710.817.8617.926.4818.5821.47
ROCE (%)15.944.043.957.8412.839.4420.9933.6223.4927.55
Asset Turnover Ratio0.830.540.610.650.730.70.80.910.740.79
PAT to CFO Conversion(x)0.8514.383.562.360.941.470.871.230.96
Working Capital Days
Receivable Days93.20129.309884.7079.4086.7091.3086.1085.2077.30
Inventory Days81.30107100.6098.609198.4083.4073.709180.80
Payable Days121.40166.60126.10117.10115.20120.80114.70119142.70130.30

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.002.29
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Neuland Laboratories Ltd FAQs

The current trading price of Neuland Laboratories on 20-Jul-2026 16:59 is ₹18,942.1.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 19-Jul-2026 the market cap of Neuland Laboratories stood at ₹23,636.3 Cr

The latest P/E ratio of Neuland Laboratories as of 19-Jul-2026 is 65.09.

The latest P/B ratio of Neuland Laboratories as of 19-Jul-2026 is 12.67.

The 52-week high of Neuland Laboratories is ₹20,072 and the 52-week low is ₹11,500.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Neuland Laboratories is ₹2,023 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Neuland Laboratories Ltd is a average quality company.

The key valuation ratios of Neuland Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Neuland Laboratories Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Neuland Laboratories Ltd

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.

It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.

Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.

Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.

The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.

Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Product range of the company includes:

  • Anti -Asthmatics
  • Fluoroquinolones
  • Cardiovascular
  • CNS
  • Corticosteroids
  • Anti-Ulcerant
  • Anti-Fungal
  • Anti-Parkinsons
  • Anti-Alzheimers

Achievements/ recognition:

  • Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
  • USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
  • Received cGMP clearance for both facilities from TGA, Australia in 2004.
  • Certificate of suitability for product itraconazole in 2006.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: